Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo Castro

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 17, 2017
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid MalignanciesBarbara Spitzer, Ann A Jakubowski, Esperanza B Papadopoulos, et al.
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 28, 2017
Impact of Toxicity on Survival for Older Adult Patients after CD34<sup>+</sup> Selected Allogeneic Hematopoietic Stem Cell TransplantationGunjan L Shah, Michael Scordo, Satyajit Kosuri, et al.
Journal of Thrombosis and Haemostasis : JTH|February 15, 2021
Heparanase expression and activity are increased in platelets during clinical sepsisAlicia S Eustes, Robert A Campbell, Elizabeth A Middleton, et al.
Blood|December 6, 2011
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationEkaterina Doubrovina, Banu Oflaz-Sozmen, Susan E Prockop, et al.
Advances in Cell and Gene Therapy|November 7, 2022
Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34<sup>+</sup>-selected allogeneic transplantationChristina Cho, Patrick Hilden, Scott T Avecilla, et al.
Bone Marrow Transplantation|April 28, 2022
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplantMaria Sola, Valkal Bhatt, Meighan Palazzo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 30, 2016
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34<sup>+</sup> Selected Grafts for Allogeneic Hematopoietic Cell TransplantationPere Barba, Ravin Ratan, Christina Cho, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2017
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic MalignanciesSatyajit Kosuri, Diego Adrianzen Herrera, Michael Scordo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2018
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34<sup>+</sup> Selected and Unmodified Hematopoietic Stem Cell TransplantationRoni Tamari, Betul Oran, Patrick Hilden, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 17, 2017
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid MalignanciesBarbara Spitzer, Ann A Jakubowski, Esperanza B Papadopoulos, et al.
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 28, 2017
Impact of Toxicity on Survival for Older Adult Patients after CD34<sup>+</sup> Selected Allogeneic Hematopoietic Stem Cell TransplantationGunjan L Shah, Michael Scordo, Satyajit Kosuri, et al.
Journal of Thrombosis and Haemostasis : JTH|February 15, 2021
Heparanase expression and activity are increased in platelets during clinical sepsisAlicia S Eustes, Robert A Campbell, Elizabeth A Middleton, et al.
Blood|December 6, 2011
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationEkaterina Doubrovina, Banu Oflaz-Sozmen, Susan E Prockop, et al.
Advances in Cell and Gene Therapy|November 7, 2022
Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34<sup>+</sup>-selected allogeneic transplantationChristina Cho, Patrick Hilden, Scott T Avecilla, et al.
Bone Marrow Transplantation|April 28, 2022
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplantMaria Sola, Valkal Bhatt, Meighan Palazzo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 30, 2016
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34<sup>+</sup> Selected Grafts for Allogeneic Hematopoietic Cell TransplantationPere Barba, Ravin Ratan, Christina Cho, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2017
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic MalignanciesSatyajit Kosuri, Diego Adrianzen Herrera, Michael Scordo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2018
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34<sup>+</sup> Selected and Unmodified Hematopoietic Stem Cell TransplantationRoni Tamari, Betul Oran, Patrick Hilden, et al.
Pageof 9